ACTRN12623001020673招募中Unknown
A multi-centre, single-arm, phase II feasibility study of the feasibility and acceptability of meditation on symptoms of psycho-existential distress and anxiety in people with advanced cancer who are receiving palliative care.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit(—)
- 性别
- All
入选标准
- •1. Aged greater than or equal to 18 years
- •2.Clinician responds ‘no’ to the surprise question ‘Would you be surprised if the patient were to die within the next 12 months
- •3.The patient has a life expectancy of at least 3 months in the opinion of the treating clinician
- •4.Screen positive for psycho-existential distress (PESAS subscale score greater than or equal to 4)
- •5.Sufficient English to participate in interviews, study interventions and complete questionnaires
- •6.Able to maintain attention for 20 minutes
- •7.Willing to provide informed written, digital or audio-recorded consent.
排除标准
- •1.Cognitive impairment to the extent that it impairs patients from completing questionnaires and interviews describing their experiences
- •2.Pre-existing severe psychotic illness (e.g., poorly controlled psychosis, schizo-affective disorder, manic bipolar disorder)
- •3.New onset or re-occurrence of post-traumatic stress disorder within the last month
- •4.Delirium (clinician assessed)
- •5.Terminal phase (Palliative care Outcomes Collaboration (PCOC) Phase 4.
研究者
相似试验
进行中(未招募)
1 期
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - RAMSETEEUCTR2008-006182-88-DEovartis Pharma Services AG69
进行中(未招募)
不适用
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - RAMSETEEUCTR2008-006182-88-NLovartis Pharma Services AG69
进行中(未招募)
1 期
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in EuropeEUCTR2008-006182-88-SEovartis Pharma Services AG69
进行中(未招募)
1 期
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in EuropeEUCTR2008-006182-88-GBovartis Pharma Services AG73
进行中(未招募)
1 期
A clinical trial investigating the use of BTT1023 in patients with PSCPrimary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2014-002393-37-GBniversity of Birmingham23
